{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-003319","form_type":"8-K","ticker":"VXRT","cik":"0000072444","company_name":"Vaxart, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.200590+00:00","generated_at":"2026-05-27T00:38:51.464282+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vaxart secures $105.9M BARDA funding increase; Phase 2b trial to test KP.2 vaccine vs mRNA","bullets":["Total BARDA funding for the Phase 2b trial now $240.1M, up from $134.2M.","Next trial portion will enroll 10,000 participants comparing Vaxart's KP.2 oral vaccine against an mRNA KP.2 comparator.","Sentinel cohort of 400 (XBB vs mRNA XBB) completed; DSMB recommended proceed without modification.","Vaxart awaiting BARDA approval to commence dosing in the KP.2 portion.","Funding increase supports manufacturing of new KP.2 lots and expanded clinical activities."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-003319","json":"https://secwatch.observer/filing/0001437749-25-003319.json","markdown":"https://secwatch.observer/filing/0001437749-25-003319.md","text":"https://secwatch.observer/filing/0001437749-25-003319.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/72444/000143774925003319/0001437749-25-003319-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/72444/000143774925003319/vxrt20250210_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:38:51.464282+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}